BioCentury | Sep 12, 2011
Company News

Marina Biotech management update

...Wash. Business: Cancer, Endocrine/Metabolic Hired: Alan Dunton as consulting CMO from president and CEO of Panacos Pharmaceuticals Inc....
BioCentury | Jan 20, 2011
Distillery Therapeutics

Indication: Infectious disease

...the oral HIV capsid protein inhibitor bevirimat dimeglumine in Phase II testing for the indication. Panacos Pharmaceuticals Inc....
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Infectious disease

...is in Phase IIb testing to treat HIV. In January, Myriad bought the compound from Panacos Pharmaceuticals Inc....
BioCentury | Feb 16, 2009
Company News

Panacos management update

Panacos Pharmaceuticals Inc. (NASDAQ:PANC), Watertown, Mass. Business: Infectious Departing: Scott McCallister as CMO WIR Staff Infectious...
BioCentury | Jan 26, 2009
Company News

Myriad Genetics, Panacos deal

...Myriad acquired from Panacos all rights to bevirimat (PA-457) for $7 million in cash. The compound...
...of infectious particles is in Phase IIb testing for HIV, with data expected this quarter. Panacos...
...HIV/AIDS infection (see BioCentury, Dec. 15, 2008). Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Panacos Pharmaceuticals Inc....
BioCentury | Jan 26, 2009
Product Development

Panacos Chronicles

...Panacos Chronicles Panacos (NASDAQ:PANC) fell 62% to $0.07 per share last week, giving it a $3.7...
...3/11/05 - Public company V. I. Technologies merges with privately held Panacos B. 8/22/05 - Panacos...
...a Phase IIa trialC. 10/6/05 - Panacos raises $86.6M in a bumped-up follow-onD. 12/20/06 - Panacos...
BioCentury | Jan 26, 2009
Analyst Picks & Changes

Analyst picks & changes

...from $1.39 after Myriad said it will pay $7 million up front for bevirimat from Panacos...
BioCentury | Jan 26, 2009
Product Development

First class letdown

...In September 2005, Panacos Pharmaceuticals Inc. was a rising star with a $500 million market cap and a...
...equivalent to 100 mg liquid. Panacos fell $1.75 (31%) to $3.94 on the news (see "Panacos...
...Myriad didn't buy Panacos outright because the company felt its internal early-stage pipeline was superior. Panacos...
BioCentury | Jan 22, 2009
Company News

Myriad acquires Panacos' bevirimat

...Myriad (NASDAQ:MYGN) acquired from Panacos (NASDAQ:PANC) all rights to bevirimat ( PA-457 ) for $7 million...
...protein and blocks the production of infectious particles is in Phase IIb testing for HIV. Panacos...
...is PA-161, an oral fusion inhibitor in preclinical testing to treat HIV/AIDS infection. On Wednesday, Panacos...
BioCentury | Jan 5, 2009
Finance

Restructuring watch

...the primary endpoint in a Phase IIb trial to treat diabetic neuropathic pain (DNP) 12/10/08 Panacos...
Items per page:
1 - 10 of 211
BioCentury | Sep 12, 2011
Company News

Marina Biotech management update

...Wash. Business: Cancer, Endocrine/Metabolic Hired: Alan Dunton as consulting CMO from president and CEO of Panacos Pharmaceuticals Inc....
BioCentury | Jan 20, 2011
Distillery Therapeutics

Indication: Infectious disease

...the oral HIV capsid protein inhibitor bevirimat dimeglumine in Phase II testing for the indication. Panacos Pharmaceuticals Inc....
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Infectious disease

...is in Phase IIb testing to treat HIV. In January, Myriad bought the compound from Panacos Pharmaceuticals Inc....
BioCentury | Feb 16, 2009
Company News

Panacos management update

Panacos Pharmaceuticals Inc. (NASDAQ:PANC), Watertown, Mass. Business: Infectious Departing: Scott McCallister as CMO WIR Staff Infectious...
BioCentury | Jan 26, 2009
Company News

Myriad Genetics, Panacos deal

...Myriad acquired from Panacos all rights to bevirimat (PA-457) for $7 million in cash. The compound...
...of infectious particles is in Phase IIb testing for HIV, with data expected this quarter. Panacos...
...HIV/AIDS infection (see BioCentury, Dec. 15, 2008). Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Panacos Pharmaceuticals Inc....
BioCentury | Jan 26, 2009
Product Development

Panacos Chronicles

...Panacos Chronicles Panacos (NASDAQ:PANC) fell 62% to $0.07 per share last week, giving it a $3.7...
...3/11/05 - Public company V. I. Technologies merges with privately held Panacos B. 8/22/05 - Panacos...
...a Phase IIa trialC. 10/6/05 - Panacos raises $86.6M in a bumped-up follow-onD. 12/20/06 - Panacos...
BioCentury | Jan 26, 2009
Analyst Picks & Changes

Analyst picks & changes

...from $1.39 after Myriad said it will pay $7 million up front for bevirimat from Panacos...
BioCentury | Jan 26, 2009
Product Development

First class letdown

...In September 2005, Panacos Pharmaceuticals Inc. was a rising star with a $500 million market cap and a...
...equivalent to 100 mg liquid. Panacos fell $1.75 (31%) to $3.94 on the news (see "Panacos...
...Myriad didn't buy Panacos outright because the company felt its internal early-stage pipeline was superior. Panacos...
BioCentury | Jan 22, 2009
Company News

Myriad acquires Panacos' bevirimat

...Myriad (NASDAQ:MYGN) acquired from Panacos (NASDAQ:PANC) all rights to bevirimat ( PA-457 ) for $7 million...
...protein and blocks the production of infectious particles is in Phase IIb testing for HIV. Panacos...
...is PA-161, an oral fusion inhibitor in preclinical testing to treat HIV/AIDS infection. On Wednesday, Panacos...
BioCentury | Jan 5, 2009
Finance

Restructuring watch

...the primary endpoint in a Phase IIb trial to treat diabetic neuropathic pain (DNP) 12/10/08 Panacos...
Items per page:
1 - 10 of 211